Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1258866.RAlobiuqoBPFLhxZctYTWFe4xB635kVU4CCCSpj286Fo4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1258866.RAlobiuqoBPFLhxZctYTWFe4xB635kVU4CCCSpj286Fo4130_assertion type Assertion NP1258866.RAlobiuqoBPFLhxZctYTWFe4xB635kVU4CCCSpj286Fo4130_head.
- NP1258866.RAlobiuqoBPFLhxZctYTWFe4xB635kVU4CCCSpj286Fo4130_assertion description "[Clinical trials using new agents targeting genetic alterations (driver mutations) in lung cancer have demonstrated significant improvements in patient outcomes (for example, gefitinib, erlotinib or crizotinib for lung adenocarcinomas harboring EGFR mutations or EML4-ALK fusions, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1258866.RAlobiuqoBPFLhxZctYTWFe4xB635kVU4CCCSpj286Fo4130_provenance.
- NP1258866.RAlobiuqoBPFLhxZctYTWFe4xB635kVU4CCCSpj286Fo4130_assertion evidence source_evidence_literature NP1258866.RAlobiuqoBPFLhxZctYTWFe4xB635kVU4CCCSpj286Fo4130_provenance.
- NP1258866.RAlobiuqoBPFLhxZctYTWFe4xB635kVU4CCCSpj286Fo4130_assertion SIO_000772 25626064 NP1258866.RAlobiuqoBPFLhxZctYTWFe4xB635kVU4CCCSpj286Fo4130_provenance.
- NP1258866.RAlobiuqoBPFLhxZctYTWFe4xB635kVU4CCCSpj286Fo4130_assertion wasDerivedFrom befree-2016 NP1258866.RAlobiuqoBPFLhxZctYTWFe4xB635kVU4CCCSpj286Fo4130_provenance.
- NP1258866.RAlobiuqoBPFLhxZctYTWFe4xB635kVU4CCCSpj286Fo4130_assertion wasGeneratedBy ECO_0000203 NP1258866.RAlobiuqoBPFLhxZctYTWFe4xB635kVU4CCCSpj286Fo4130_provenance.